Yuzhuo Z. Wang

Longitudinal single-cell RNA sequencing of a neuroendocrine transdifferentiation model reveals transcriptional reprogramming in treatment-induced neuroendocrine prostate cancer

This study uses longitudinal scRNA-seq to track neuroendocrine transdifferentiation in a prostate cancer model, identifying transcriptional changes and key regulators during treatment-induced NEPC progression.

A Stress-Adaptive Lipid Kinase Axis Defines Metabolic Vulnerabilities in Neuroendocrine Prostate Cancer

This study identifies a stress-lipid kinase axis in NEPC driven by PIKfyve, revealing a synthetic vulnerability between PIKfyve and FASN that can be exploited for therapeutic targeting.

MZF1-mediated GAPDH overexpression drives glycolytic reprogramming and neuroendocrine progression in advanced prostate cancer

This study identifies MZF1-mediated GAPDH overexpression as a driver of glycolytic reprogramming and neuroendocrine progression in advanced prostate cancer, suggesting metabolic targeting as a therapeutic strategy.

Pharmacological targeting of EED is an effective therapeutic strategy in cellular models of incurable neuroendocrine prostate cancer

This study compares tazemetostat and ORIC-944 in NEPC and PRAD cells, finding ORIC-944 more effective in inducing apoptosis and growth inhibition.

Disruption of NUAK2-Mediated RNA Splicing by Trilaciclib Reveals a Therapeutic Vulnerability in AR-Indifferent Prostate Cancer

This paper identifies NUAK2 as a therapeutic target in AR-indifferent prostate cancer, showing trilaciclib inhibits NUAK2 and suppresses tumor growth.

Longitudinal single-cell profiling links RUNX1T1 to lineage transition and maintenance in treatment-induced neuroendocrine prostate cancer

This study uses longitudinal single-cell RNA sequencing to identify RUNX1T1 as a key regulator in the transition and maintenance of treatment-induced neuroendocrine prostate cancer.

A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate cancer

This study identifies Neurog2 as a potential therapeutic target for MYCN-driven neuroendocrine prostate cancer by showing its role in promoting tumor growth and NEPC development.

Identifying Rare Germline Variants Associated with Metastatic Prostate Cancer Through an Extreme Phenotype Study

This study identifies rare germline variants associated with metastatic prostate cancer using an extreme phenotype cohort and validates their functional impact.

Deciphering the Transcription Factor Landscape in Neuroendocrine Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation

This study identifies lineage-specific transcription factor profiles in prostate cancer progression, revealing dynamic shifts during NE transdifferentiation and proposing a three-phase model.

5'-S-(3-aminophenyl)-5'-thioadenosine, a novel chemoprotective agent for reducing toxic side effects of fluorouracil in treatment of MTAP-deficient cancers

This paper identifies m-APTA, an MTA analogue that reduces NBA toxicity without hypothermia, improving safety for MTAP-deficient cancer treatment.

EZH2 inhibition enhances the activity of platinum chemotherapy in aggressive variant prostate cancer

This study shows that EZH2 inhibition enhances platinum chemotherapy effectiveness in aggressive variant prostate cancer by reducing H3K27me3 and modulating DNA repair and apoptosis pathways.

CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality

This study shows CDK12 loss drives prostate cancer development and identifies CDK13 as a therapeutic target through paralog-based synthetic lethality in CDK12-mutant tumors.